Press Release
<p>FERRING PHARMACEUTICALS APPOINTS WILLIAM GARBARINI AS SENIOR DIRECTOR OF MARKETING</p>
<p><strong>Responsible for Marketing for Newly Created Orthopedics/Urology Business Unit</strong> </p>
<table class="newsroom">
<tr>
<td valign="top" width="57"><p><b>Contact:</b></p></td>
<td width="20" valign="top"></td>
<td width="304">
<p>Kelly Laban<br>
Kovak-Likly Communications<br>
(203)762-8833 x15 or KLaban@KLCpr.com</p>
</td>
</tr>
</table>
<p>Pictured: William N. Garbarini, Jr., appointed senior director of
marketing for the Orthopedics/Urology Business Unit for Ferring
Pharmaceuticals </p>
<p>Suffern, NY – May 11, 2005 – Ferring Pharmaceuticals Inc. announced that
William N. Garbarini, Jr. has been appointed senior director of marketing for
its new Orthopedics/Urology Business Unit. In his new role, Garbarini will be
responsible for the strategic direction and implementation of marketing programs
for products with significant growth potential in these therapeutic areas.</p>
<p>“Bill excelled in his role as director of marketing for the infertility product
line and in his responsibilities for the company’s out-license relationships,”
said Wayne Anderson, president. “With his proven track record, we are confident
that he will lead the newly created business unit’s marketing efforts to great
success.” </p>
<p>In his new capacity, Garbarini is responsible for marketing NUFLEXXA™, an
injectable hyaluronic acid for pain from knee osteoarthritis. He will continue
to be responsible for the out- license relationships of DDAVP (Aventis) and
Pentasa (Shire). Garbarini joined Ferring in 2001 as product director. In 2002, he was promoted to director of marketing for
Ferring’s infertility products, and was also responsible for the out-license
relationships of DDAVP and Pentasa. </p>
<p>Prior to joining Ferring, Garbarini was director, client services for Caresoft,
Inc. and product manager for the Proventil<sup>®</sup> family of inhaled asthma medications
at Schering-Plough Corporation/ Key Pharmaceuticals. </p>
<p><strong>About Ferring Pharmaceuticals Inc.</strong><br/>
Ferring Pharmaceuticals Inc., part of the Ferring Group, a privately owned,
international pharmaceutical company, markets MENOPUR<sup>®</sup> (menotropins for
injection, USP), BRAVELLE<sup>®</sup> (urofollitropin for injection, purified), REPRONEX<sup>®</sup> (menotropins
for injection, USP) and NOVAREL™ (chorionic gonadotropin for injection, USP) in
the U.S. to infertility specialists and their patients. Ferring also offers the
Q∙CAP™, the first and only needle-free reconstitution device, for use with its
fertility treatments. Ferring’s line of orthopedic and urology products include
NUFLEXXA™, hyaluronic acid for pain from osteoarthritis in the knee and
DEGARELIX for prostate cancer (Phase III). Other products include ACTHREL<sup>®</sup> (corticorelin
ovine triflutate for injection) for the differential diagnosis of Cushing’s
syndrome and generic DESMOPRESSIN ACETATE in injectable and rhinal tube forms
for the treatment of diabetes insipidus and primary nocturnal enuresis. The
Ferring Group specializes in the research, development and commercialization of
compounds in general and pediatric endocrinology, urology, gastroenterology,
obstetrics/gynecology and infertility. For more information, visit
www.ferringusa.com. </p>
<p># # # </p>
EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used in people who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.
Important Safety Information
You should not receive this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products. You should not have an injection into the knee if you have a knee joint infection or if you have skin disease or infection around the injection site.
EUFLEXXA is only for injection into the knee performed by a qualified doctor. After you receive this injection you may need to avoid activities such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour). The safety and effectiveness of repeat treatment cycles of EUFLEXXA have not been established. The safety and effectiveness of EUFLEXXA have not been shown in people under 18 years of age.
Side effects sometimes seen when EUFLEXXA is injected into the knee joint were pain, swelling, skin irritation, and tenderness and these were generally mild and did not last long.
Please see Full Prescribing Information.
Please see Important Information for Patients.
Patient Treatment Information
PLEASE CONSULT WITH YOUR DOCTOR, OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL BEFORE USING ANY PRODUCT DISCUSSED WITHIN THIS WEB SITE.
This website is intended only for US residents.
Euflexxa® is a registered trademark of Ferring Pharmaceuticals Inc.
